Back
Compare AU
Compare ASIA vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Asia Technology Tigers ETF (ASIA) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
ASIA | CURE | |
|---|---|---|
Popularity | Medium | Low |
Pearlers invested | 1,165 | 73 |
Median incremental investment | $990.50 | $660.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,613.60 | $1,671.85 |
Average age group | 26 - 35 | > 35 |
Key Summary
ASIA | CURE | |
|---|---|---|
Strategy | ASIA aims to track the performance of the Solactive Asia Ex-Japan Technology & Internet Tigers index. The index consists of the 50 largest technology and online retail stocks in Asia (excluding Japan). | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | SK HYNIX INC (11.23 %) SAMSUNG ELECTRONICS CO LTD (10.83 %) TAIWAN SEMICONDUCTOR MANUFACTU (9.66 %) | Avidity Biosciences Inc Ordinary Shares (2.52 %) Revolution Medicines Inc Ordinary Shares (2.22 %) Insmed Inc (2.15 %) |
Top 3 industries | Other (78.96 %) Communication Services (11.73 %) Consumer Discretionary (8.74 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | China (43.17 %) Taiwan (31.14 %) Korea (13.68 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.67 % | 0.45 % |
Key Summary
ASIA | CURE | |
|---|---|---|
Issuer | BetaShares | Global X |
Tracking index | Solactive Asia Ex-Japan Technology & Internet Tigers Index | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.67 % | 0.45 % |
Price | $14.85 | $57.65 |
Size | $953.823 million | $36.750 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.19 % | 5.08 % |
Market | ASX | ASX |
First listed date | 21/09/2018 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
ASIA | CURE | |
|---|---|---|
Popularity | Medium | Low |
Pearlers invested | 1,165 | 73 |
Median incremental investment | $990.50 | $660.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,613.60 | $1,671.85 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
ASIA | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
ASIA | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |